A new paper published in the Annals of Rheumatic Diseases found significant differences in the three main classes of rheumatoid arthritis drugs. The study used real-world data (RWD) from a European registry dataset of almost 32,000 rounds of treatment given to RA patients, showing that abatacept had demonstrably worse remission rates than TNF inhibitors.
According to John Gever, “Rates of discontinuation (after adjustment for confounders) were similar overall among the four drug types, but not when analyzed by reason. Relative to TNF inhibitors, patients on JAK and IL-6 inhibitors were significantly less likely to stop treatment for ineffectiveness.”
To learn more, click here.
(Source: MedPage Today, June 16, 2022)